Status:
TERMINATED
Study of South African Dialysis Patients
Lead Sponsor:
Amgen
Conditions:
Chronic Kidney Disease, Receiving Dialysis
Eligibility:
All Genders
18-99 years
Brief Summary
An observational study to describe the treatment of anaemia in patients with chronic kidney disease, who are receiving dialysis treatment at selected study centres in South Africa.
Detailed Description
This multicentre, prospective, observational study will describe the treatment and clinical outcomes of of dialysis patients in South Africa. No formal hypothesis will be tested in this descriptive st...
Eligibility Criteria
Inclusion
- Adult patients undergoing chronic haemodialysis or peritoneal dialysis
- Commenced Aranesp therapy 3-6 months prior to enrolment
- Erythropoiesis stimulating agent (ESA) naive or treated with another ESA prior to commencing Aranesp
- Informed consent obtained
Exclusion
- Received Aranesp in an interventional study within 6 months prior to start of observation period
- Receive investigational product during the observation period
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01890577
Start Date
April 1 2013
End Date
January 1 2014
Last Update
July 12 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Glenwood, KwaZulu-Natal, South Africa, 4083
2
Research Site
Umhlanga, KwaZulu-Natal, South Africa, 4320
3
Research Site
Cape Town, Western Cape, South Africa, 7800
4
Research Site
Durban, South Africa, 4001